z-logo
Premium
Adoptive T Cell Immunotherapy for Treatment of Ganciclovir‐Resistant Cytomegalovirus Disease in a Renal Transplant Recipient
Author(s) -
Macesic N.,
Langsford D.,
Nicholls K.,
Hughes P.,
Gottlieb D. J.,
Clancy L.,
Blyth E.,
Micklethwaite K.,
Withers B.,
Majumdar S.,
Fleming S.,
Sasadeusz J.
Publication year - 2015
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.13023
Subject(s) - medicine , ganciclovir , cytomegalovirus , immunotherapy , transplantation , immunology , glomerulopathy , valganciclovir , thrombotic microangiopathy , salvage therapy , disease , human cytomegalovirus , herpesviridae , immune system , virus , viral disease , chemotherapy , kidney , glomerulonephritis
Cytomegalovirus (CMV) is a significant cause of morbidity, mortality and graft loss in solid organ transplantation (SOT). Treatment options for ganciclovir‐resistant CMV are limited. We describe a case of ganciclovir‐resistant CMV disease in a renal transplant recipient manifested by thrombotic microangiopathy‐associated glomerulopathy. Adoptive T cell immunotherapy using CMV‐specific T cells from a donor bank was used as salvage therapy. This report is a proof‐of‐concept of the clinical and logistical feasibility of this therapy in SOT recipients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here